Table 3.
Proportional lipid response associations (per allele) for literature-based candidate single nucleotide polymorphisms that were selected for custom genotyping and that reached statistical significance (P < 0.001)a
| SNP | Chr | Nearby gene(s)/locus | n | Effect/other allele | Effect allele freq | LDL-C response |
ApoB response |
||
|---|---|---|---|---|---|---|---|---|---|
| Additional % reductionb (95% CI) | P-value | Additional % reductionb (95% CI) | P-value | ||||||
| rs646776 | 1 | CELSR2/PSRC1/SORT1 | 18 289 | C/T | 0.21 | 0.47 (0.13, 0.80) | 6.7 × 10−3 | 0.76 (0.47, 1.05) | 2.4 × 10−7 |
| rs3798220 | 6 | LPA | 14 472 | C/T | 0.02 | −2.30 (−3.47, −1.15) | 7.1 × 10−5 | −2.09 (−3.09, −1.11) | 2.5 × 10−5 |
| rs10455872 | 6 | LPA | 14 462 | G/A | 0.09 | −3.15 (−3.74, −2.58) | 8.1 × 10−28 | −2.86 (−3.35,−2.36) | 6.5 × 10−31 |
| rs2002042 | 10 | ABCC2 | 18 027 | T/C | 0.25 | 0.65 (0.33, 0.97) | 8.2 × 10−5 | 0.56 (0.28, 0.83) | 7.5 × 10−5 |
| rs11045819 | 12 | SLCO1B1 | 14 338 | A/C | 0.16 | 0.92 (0.49, 1.34) | 2.4 × 10−5 | 0.66 (0.29, 1.02) | 4.3 × 10−4 |
| rs4149056 | 12 | SLCO1B1 | 16 867 | C/T | 0.15 | −1.15 (−1.57, −0.74) | 5.0 × 10−8 | −0.96 (−1.31, −0.60) | 1.0 × 10−7 |
| rs4803750 | 19 | APOE Cluster | 18 326 | G/A | 0.07 | 1.22 (0.68, 1.74) | 8.5 × 10−6 | 1.21 (0.75, 1.66) | 2.6 × 10−7 |
| rs2075650 | 19 | APOE Cluster | 18 265 | G/A | 0.14 | −0.82 (−1.22, −0.41) | 7.8 × 10−5 | −0.77 (−1.12, −0.42) | 1.3 × 10−5 |
| rs7412 | 19 | APOE Cluster | 14 455 | T/C | 0.08 | 2.55 (1.98, 3.11) | 4.8 × 10−18 | 2.84 (2.35, 3.32) | 4.9 × 10−29 |
| rs4420638 | 19 | APOE Cluster | 14 388 | G/A | 0.18 | −0.96 (−1.38, −0.54) | 6.4 × 10−6 | −0.91 (−1.27, −0.55) | 5.7 × 10−7 |
aResults are ordered by chromosomal position. Results for all literature-based candidate SNPs selected for custom genotyping are shown in Supplementary material online, Table S3 and S4.
bThe average proportional LDL-C reduction in response to simvastatin 40 mg daily was 42.36% and the average proportional reduction in ApoB was 32.76%.